Alterity Therapeutics (ATHE) announced that the peer-reviewed journal, Metallomics has published data on the importance of iron and iron-targeting agents like ATH434 to treat neurodegenerative diseases. Metallomics publishes cutting-edge investigations that elucidate the dynamics, role, and impact of metals in biological systems. The publication, entitled, “ATH434, a promising iron-targeting compound for treating iron regulation disorders” was led by author Ashley Pall, Department of Pharmaceutical Sciences at Wayne State University. The publication describes how ATH434 targets the toxic form of iron that drives the pathology of a rare neurodegenerative disease known as Friedreich’s Ataxia.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATHE:
- Alterity Therapeutics reports cash balance of A$9.28M as of September 30
- Alterity Therapeutics to Present at Healthcare Summit
- Alterity Therapeutics presents data on neuroprotection of ATH434
- Alterity Therapeutics presents data on ATH434 at MDS Congress
- Alterity Therapeutics appoints Abby Macnish Niven as CFO